<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04061655</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 03/ 2019</org_study_id>
    <nct_id>NCT04061655</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion</brief_title>
  <official_title>Effect of Intravenous Iron Supplementation in Reducing Allogenic Blood Transfusion and Improving Outcomes in Patients Undergoing CABG. A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 80 patients will be randomly allocated into 2 groups, group A and placebo group
      using concealed envelope method.Group A patients (n= 40)will receive single dose intravenous
      infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
      Patients in the placebo group (n=40) will receive as a single-dose of saline (Natriumklorid 9
      mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 80 patients will randomly allocated into 2 groups, group A and placebo group using
      concealed envelope method.Group A patients (n= 40) will receive single dose intravenous
      infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
      Patients in the placebo group (n=40) will receive as a single-dose of saline (Natriumklorid 9
      mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.

      General anesthesia will the institutional standards and all surgeries will be performed by
      the same surgical team.Standardized monitoring will be applied.After median sternotomy,CPB
      will be established with 1500 ml crystalloid priming volume and mild hypothermia (32°C) with
      a Trillium Affinity oxygenator (Medtronic,Minneapolis, Minnesota, USA) and a Sarns CPB
      machine (Harrison, Mt. Clemens, Michigan, USA) at a flow rate of 2.6 lmin−1m−2.Myocardial
      protection will be done using cold blood cardioplegia at 20°C. During CPB, homologous donor
      packed red blood cells will be transfused if hemoglobin was less than 6.5 gdl−1.During
      bypass, anticoagulation for extracorporeal circulation was performed using heparin 300 U/kg
      administered into the right atrium. Acelite activated clotting time (ACT) greater than 400
      was considered adequate for commencing CPB; if less, an additional dose of 100Uof heparin
      will be adminstered.CPB will be conducted using nonocclusive roller pumps, arterial line
      filtration ,membrane oxygenators, , and blood-enriched cold hyperkalemic arrest. Systemic
      hypothermia documented by an esophageal temperature of 32°C will be maintained during aortic
      cross clamping.After completion of CPB and removal of the arterial cannula, heparin will be
      neutralized with 1 mg of protamine sulfate adminstered for every 100U of heparin over a
      period of 15 minutes . Eventually, a second dose of protamine 50 mg will be given if ACT
      remained above baseline. All patients will be transferred to ICU after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Actual">January 10, 2020</completion_date>
  <primary_completion_date type="Actual">January 6, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>haemoglobin concentration change</measure>
    <time_frame>1 week after discharge from hospital</time_frame>
    <description>the change in the Hb concentration at baseline, intraoperative, at discharge and 1 week after discharge in non-anaemic patients undergoing cardiac surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>7 to 10 days</time_frame>
    <description>duration of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Complications</condition>
  <arm_group>
    <arm_group_label>iron therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Isomaltoside 1000</intervention_name>
    <description>Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.</description>
    <arm_group_label>iron therapy group</arm_group_label>
    <other_name>iron therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged 52-73 years old

          -  ASA II/III

          -  elective CABG

          -  hemoglobin level at baseline for males &gt;13.0 g/dl and for females &gt;12.0 g/dl.

        Exclusion Criteria:

          -  Patients with known hypersensitivity to iron sucrose

          -  history of hepatitis B or C or human immunodeficiency virus

          -  folate or vitamin B12deficiency, history of unstable angina,

          -  active severe infection

          -  suspicion of iron overload (ferritin &gt; 300 μg/l ), or autologous blood transfusion in
             the previous month pregnancy and nursing impaired renal function defined by
             s-creatinine &gt;150 μmol/L patients received any iron preparations in the previous month
             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>52 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman Shoeb, professor</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams university</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 17, 2019</study_first_submitted>
  <study_first_submitted_qc>August 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>January 18, 2020</last_update_submitted>
  <last_update_submitted_qc>January 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hoda Shokri</investigator_full_name>
    <investigator_title>Associate professor of Anesthesia</investigator_title>
  </responsible_party>
  <keyword>CABG</keyword>
  <keyword>iron therapy</keyword>
  <keyword>blood transfusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Iron isomaltoside 1000</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study protocol statistical analysis data analysis</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>6 months</ipd_time_frame>
    <ipd_access_criteria>Descriptive statistics will be carried out for numerical parametric data and presented as mean±SD, whereas categorical data will be presented as number and percentage. Variables such as demographic data and comorbidities will be compared using the χ2-test</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

